Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Dose Titration Study of JNJ-37822681 in Patients With Stable Schizophrenia
2007-007669-20Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-37822681 in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of JNJ-37822681, Striatal D2 dopamine receptor occupancy and 1 more. Started Apr 2008; status: completed.
02
Drugs
JNJ-37822681
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2007-007669-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007669-20.